Merck Reports observational study Data for Danicopan in Biliary tract cancer

Merck today announced observational study results for Danicopan in patients with Biliary tract cancer. The study demonstrated that Danicopan demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Biliary tract cancer and support the continued development of Danicopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Danicopan was consistent with previous observations, with no new safety signals identified.